<DOC>
	<DOCNO>NCT01808248</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , antiviral efficacy sofosbuvir ( SOF ) combination peginterferon alfa 2a ( PEG ) ribavirin ( RBV ) administer 12 week participant chronic genotype 2 3 hepatitis C virus ( HCV ) infection previously fail prior treatment interferon-based regimen .</brief_summary>
	<brief_title>Sofosbuvir ( GS-7977 ) Combination With PEG Ribavirin 12 Weeks Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 3</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Infection genotype 2 3 HCV infection Cirrhosis determination Individual treatmentexperienced Screening laboratory value within defined threshold Individual treat investigational drug device within 30 day Screening visit Use highly effective contraception method female childbearing potential sexually active male Prior exposure directacting antiviral drug target HCV NS5B polymerase Pregnant nursing female male pregnant female partner Current prior history clinical hepatic decompensation History clinicallysignificant illness major medical disorder may interfere treatment , assessment , compliance study protocol Excessive alcohol ingestion significant drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>HCV genotype 2 ( GT-2 )</keyword>
	<keyword>HCV genotype 3 ( GT-3 )</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>Treatment-Na√Øve</keyword>
	<keyword>GS-7977</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>RBV</keyword>
	<keyword>Peginterferon Alfa 2a</keyword>
	<keyword>PEG</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis A</keyword>
	<keyword>Hepatitis , Chronic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis , Viral , Human</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Enterovirus Infections</keyword>
	<keyword>Picornaviridae Infections</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>Peginterferon alfa-2a</keyword>
	<keyword>Interferon-alpha</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Physiological Effects Drugs</keyword>
</DOC>